Sign in Subscribe
Type 2 diabetes

Dual Approach to Type 2 Diabetes Management Shows Promise

Strategic Insights

— 2 min read

Research published in the Hormones-international Journal of Endocrinology and Metabolism has demonstrated the effectiveness of a dual approach to managing type 2 diabetes mellitus (T2DM). The study, conducted in Hebei, China, compared the effects of dulaglutide alone versus dulaglutide combined with probiotics on cardiovascular risk factors, pancreatic beta-cell function, and gut microbiota in patients with T2DM.

The randomized controlled trial involved 60 overweight/obese adults with T2DM, who were divided into two groups: a control group receiving dulaglutide and a placebo, and an intervention group receiving dulaglutide and probiotics containing Bifidobacterium longum. The results showed significant improvements in glycemic control, inflammatory markers, and cardiovascular risk factors in the intervention group compared to the control group.

Key Takeaways:

  • The dual approach of using dulaglutide combined with probiotics has shown promise in managing T2DM, with significant improvements in glycemic control and inflammatory markers.
  • The study involved 60 overweight/obese adults with T2DM, with a BMI of 24 kg/m² and HbA1c levels between 6.5-11%.
  • The intervention group showed greater reductions in HbA1c (- 1.06% vs. -0.35%, P = 0.028), FPG (- 4.16 vs. -3.92 mmol/L, P = 0.010), and inflammatory markers (TNF-a: -43.6% vs. -33.3%, P
  • The study concluded that a dual approach to T2DM management may offer a promising strategy, although larger long-term trials are needed to confirm cardiovascular benefits.
  • The research team, led by Yanfei Yang, included Jinxia Tian, Zijuan Yu, Yang Gao, Xiaochun Zong, Qiaojuan Wu, Haiyan Su, Wenjuan Cao, and Dandan Xu.
  • The study was published in the Hormones-international Journal of Endocrinology and Metabolism, Volume 24, Issue 3, Pages 643-650.

Statistics:

  • 60 overweight/obese adults with T2DM participated in the study.
  • The BMI of the participants was 24 kg/m², with HbA1c levels between 6.5-11%.
  • The intervention group showed a greater reduction in HbA1c (- 1.06% vs. -0.35%, P = 0.028).
  • The intervention group also showed greater reductions in FPG (- 4.16 vs. -3.92 mmol/L, P = 0.010) and inflammatory markers (TNF-a: -43.6% vs. -33.3%, P

Sources:

  • Yang, Y., Tian, J., Yu, Z., Gao, Y., Zong, X., Wu, Q., Su, H., Cao, W., & Xu, D. (2025). Comparative evaluation of dulaglutide alone vs. dulaglutide combined with probiotics on cardiovascular risk factors in T2DM. Hormones-international Journal of Endocrinology and Metabolism, 24(3), 643-650.
  • NewsRx. Reports from Yanfei Yang and Colleagues Advance Knowledge in Biomarkers (Comparative evaluation of dulaglutide alone vs. dulaglutide combined with probiotics on cardiovascular risk factors in T2DM). Obesity & Diabetes Week. October 20, 2025; p 117.

Read more